GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people

medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…

AI Summary: A large observational analysis suggests GLP‑1 receptor agonists — the headline-grabbing diabetes and weight-loss drugs — are linked to reduced risk of developing and dying from substance use disorders across multiple substances. Researchers urge cautious optimism: signals are intriguing, but causality remains unproven and more controlled trials are needed before rewriting addiction treatment playbooks.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 3 months

Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 6 months

Lilly fights classification ruling as stockpile and compounding lawsuits swirl / 3 months

Compounding Pharmacy Sues Lilly and Novo Nordisk / 4 months

FDA Removes Suicide Warnings from GLP‑1 Drugs / 4 months

Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 6 months

Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment / 5 months